November 2022 - Page 5 of 7 - CannabisNewsWire

TuesdayNov 08, 2022 4:20 pm

420 with CNW — Schumer Reveals That Cannabis Banking, Expungements Law Is Close

During a recent debate hosted by Spectrum News, Senate Majority Leader Chuck Schumer stated that Congress was very close to introducing and approving a cannabis measure with provisions to cover banking access for legal businesses and expungements of past convictions. When asked about a separate bill to legalize marijuana that he’d filed earlier this year and whether he felt it would have made more sense to promote more studies into cannabis before putting an end to prohibition, Schumer stated that while research was extremely important, most states had already approved marijuana legalization, which meant that the policy was inescapable. The…

TuesdayNov 08, 2022 11:15 am

REZYFi, Inc. Leverages Cannabis Industry Interests to Diversify Banking and Real Estate as DCC Prioritizes Research Project Funding

The California Department of Cannabis Control (“DCC”) has reserved $20 million in funding for research prioritizing cannabis projects, including potency, health impact, medicinal use, legacy cannabis genetics, and industry health The medicinal and recreational cannabis market size in the US is anticipated to reach $33 billion in 2022, with a revenue outlook of $52.6 billion by 2026 REZYFi Inc., through two wholly-owned subsidiaries, is positioned to be the first cannabis mortgage banker in the United States The state of California Department of Cannabis Control has reserved $20 million in funding for research that prioritizes numerous cannabis topics, including potency, health…

TuesdayNov 08, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Aiming to Address Unmet Patient Needs of Hypertensive Patients

Lexaria just completed its HYPER-H21-4 human clinical hypertension study, posting a sustained drop in blood pressure in normally active hypertensive patients With the success of this study, the company is working towards an IND application to seek FDA approval for its patented DehydraTECH(TM)-enabled CBD capsule formulation. 47% of adults live with hypertension but only 24% of them have it under control With its DehydraTECH-CBD, Lexaria hopes to not only address the severe unmet patient need associated with hypertension but also tap into a market that is set to be valued at $34 billion by 2030 Lexaria Bioscience (NASDAQ: LEXX), a…

TuesdayNov 08, 2022 4:20 am

420 with CNW — Delta-9 THC from Hemp Exposes Legal Loophole, Stirs Controversy

When the 2018 farm bill was passed, hemp and all its derivatives were legalized nationally as long as the hemp used didn’t exceed 0.3% THC on a dry-weight basis. In Missouri, one entrepreneur has made a seltzer using delta-9 THC extracted from hemp, and he believes his invention is perfectly legal since it isn’t made from marijuana and the total THC content doesn’t exceed the threshold set for industrial hemp. Joshua Grigaitis, the owner of a company called Mighty Kind, is the man who seems to be pushing the legal limits of the 2018 farm bill. He asserts that his…

MondayNov 07, 2022 4:20 pm

420 with CNW — Many Ohio Physicians Find Marijuana Helpful for Pain

A new survey conducted by Ohio’s state medical board has discovered that most physicians in the state who recommend medical cannabis were satisfied with the drug’s effectiveness in treating patients with cancer, pain, post-traumatic stress disorder (“PTSD”) and fibromyalgia. The state medical board surveyed 648 physicians who all possess certificates that allow them to recommend medical cannabis to patients in Ohio, between July 1, 2022, and August 31, 2022. Of the total number of licensed physicians who recommend cannabis, 583 doctors completed online surveys. It should be noted that not all doctors answered every question. The survey discovered that roughly…

MondayNov 07, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Agreement to Acquire Multi-national Cannabis Operator Positions Company for New Strategic Growth in Europe

Flora Growth is a cannabis cultivator and international brand developer with a strong base of operations at its licensed facility in northern Colombia Flora recently announced its plans to acquire multi-national operator Franchise Global Health (“FGH”), the latest of its strategic acquisitions designed to boost revenues and expand Flora’s international footprint FGH is focused on the German market, where its subsidiary was the first company to sell cannabis Germany is in turn expected to provide the companies a launching pad for success in Europe, where opportunity is defined by the fact that currently Germany provides 75 to 80 percent of…

MondayNov 07, 2022 4:20 am

420 with CNW — German Plan to Legalize Cannabis Won’t Permit Imports

The government of Germany recently published a proposal detailing its plans to legalize and regulate the recreational use of marijuana. The 12-page plan excludes cannabis imports, which means that the plant will be cultivated in the country. This will be a blow to some global producers who had plans to import their products into Germany, which is said to be the biggest economy in Europe. In a news conference last week, the country’s Health Minister, Karl Lauterbach, stated that plans were underway to ensure complete cultivation in Germany. The proposal, which was endorsed by the German cabinet, suggests that the…

FridayNov 04, 2022 4:20 pm

420 with CNW — Debt Financing Outstrips Equity in the US Cannabis Industry

According to the latest statistics from Viridian Capital Advisors, more and more marijuana companies are opting for debt financing as opposed to equity financing in the United States. Viridian Capital Advisors is a company that advises marijuana entities on strategy and M&A as well as on how to access or raise capital. According to Viridian Capital, debt financing now commands 93% of all financing secured by marijuana companies that focus on retail or cultivation, while the industry average for debt financing stands at 55.7%. It should be noted that year-to-date figures show a decline in both equity financing as well…

FridayNov 04, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Zero Adverse Effects from Successful HYPER-H21-4 Study of DehydraTECH(TM)-CBD for High Blood Pressure

The CDC reported more than 670,000 annual deaths in the United States with high blood pressure as a primary or contributing cause Lexaria's patented DehydraTECH(TM) technology has been shown, through HYPER-H21-4 study, to decrease high blood pressure in subjects through DehydraTECH-CBD-enabled dosing The global antihypertension drug market was valued at over $22.5 billion in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in a market of over $28.7 billion by 2026 In the United States, uncontrolled high blood pressure is common among adults – with only one in four having the condition under control.…

FridayNov 04, 2022 4:20 am

420 with CNW — Federal Commission Considers Amending Sentencing Guidelines on Past Cannabis Use

Before states began legalizing cannabis in the late nineties and early 2000s, the plant had been prohibited across the country for decades. Over the years, tens of thousands of Americans were convicted and imprisoned over cannabis-related charges, with a majority of them being people of color. Even though dozens of states now allow medical and recreational cannabis use, plenty of people are still held back from fully participating in life by cannabis offenses on their records. Hundreds of thousands of people have been arrested for cannabis-related offenses in the past couple of years and cannabis arrests overall make up more…